



1642
IFW

CERTIFICATE OF MAILING 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
November 9, 2005 Date	 Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Thorpe and Ran

Serial No.: 09/998,833

Filed: November 30, 2001

For: COMBINED CANCER TREATMENT
METHODS USING ANTIBODIES TO
AMINOPHOSPHOLIPIDS

Group Art Unit: 1642

Examiner: Fetterolf

Atty. Dkt. No.: 4001.002299

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that the present Supplemental Information Disclosure Statement be entered and the document listed on the enclosed Form PTO-1449 be considered by the Examiner and made of record in the present case. The required copies are enclosed, although copies of U.S. patents are no longer required under 37 C.F.R. § 1.98(a)(2)(ii).

In accordance with 37 C.F.R §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

An Official Action reflecting examination on the merits has been received in the present application. However, this Supplemental Information Disclosure Statement is being filed prior to the mailing of a final Official Action, Notice of Allowance or an Action that closes prosecution, and is timely filed in accordance with 37 C.F.R. § 1.97(c) without a fee in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the documents listed in the accompanying Form PTO-1449 were not cited in a communication from a foreign patent office in a foreign counterpart to the present application. The listed documents were cited in an Official Action on the merits in a co-pending application of one of the present inventors, U.S. Application Serial No. 10/375,741 (Attorney Docket No. 4001.001999), apparently mailed from the P.T.O. on August 10, 2005 (although not received until September 08, 2005), and could not have been submitted before receipt. The present statement is being filed within three months of the apparent mailing date of the referenced Official Action, and is thus timely.

No fees are due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason, the Examiner should contact the undersigned representative to discuss deduction from Peregrine Pharmaceuticals, Inc. Deposit Account No. 50-3493/4001.002299.

Respectfully submitted,

PEREGRINE PHARMACEUTICALS, INC.
Customer No. 000052101



Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

5353 W. Alabama, Suite 306
Houston, Texas, 77056
(832) 886-5834

Date: November 9, 2005



Form PTO-1449 (modified)		Temp. Atty. Docket No. 4001.002299	Serial No. 09/998,833
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe <i>et al.</i>	
		Filing Date: November 30, 2001	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A39	5,922,688	Jul. 13, 1999	Hung <i>et al.</i>	514	44	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B15	EP 0 458 878	Sep. 4, 1996	EPO	A61K	39/00	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C120	Greenberg <i>et al.</i> , "A Clinical Trial of Antioxidant Vitamins to Prevent Colorectal Adenoma," <i>N. Engl. J. Med.</i> , 331:141-147, 1994.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Information Disclosure Statement — PTO-1449 (Modified)